Skip to content

The effects of intravenous Dexamethasone on headache

A clinical trial comparing administration versus non-administration of intravenous Dexamethasone on the incidence of headache after spinal anesthesia in women undergoing caesarean section

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017080117756N22
Enrollment
104
Registered
2017-08-30
Start date
2013-08-16
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache. Spinal and epidural anaesthesia-induced headache during the puerperium

Interventions

Intervention 1: Control Group (distilled water or normal saline): All the patients underwent spinal anesthesia using quince 25 needle with 0.5 percent 12-15 milligram bupivacaine (topical anesthetic).
Prevention
Control Group (distilled water or normal saline): All the patients underwent spinal anesthesia using quince 25 needle with 0.5 percent 12-15 milligram bupivacaine (topical anesthetic). Then, 2 cc dist
Intervention Group (intravenous dexamethasone): All the patients underwent spinal anesthesia using quince 25 needle with 0.5 percent 12-15 milligram bupivacaine (topical anesthetic). Afterwards, 8 mil

Sponsors

Vice-Chancellery for Research and Technology of Birjand University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age from 15 to 45 years; pregnant woman of Class 1 and 2 with uncomplicated term pregnancy according to the physical status classification by the American Society of Anesthesiologists; candidature for cesarean section surgery. Exclusion criteria: Prohibition of spinal anesthesia (for example, coagulation disorders, peripheral neuropathy, infection of the needle insertion site, and spinal cord disorders); history of headache, migraine, and hypertension (as in eclampsia and preeclampsia).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Headache severity. Timepoint: 48 hours after intervention. Method of measurement: Visual Analogue Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Bibi Fatemeh Shakhs Emampour

Birjand University of Medical Sciences

f.emepour@gmail.com+98 56 3239 5600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026